Homozygous deletion of INK4a/ARF genes and overexpression of bcl-2 in relation with poor prognosis in immunocompetent patients with primary central nervous system lymphoma of the diffuse large B-cell type

Journal of Neuro-Oncology

Volumn 55, Issue 1, 2001, Pages 51-58

  Hayashi, Y ^a   Iwato, M ^a   Arakawa, Y ^a   Fujisawa, H ^a   Thoma, Y ^a   Hasegawa, M ^a   Tachibana, O ^a   Yamashita, J ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Bcl 2; INK4a ARF; Primary central nervous system lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; INHIBITOR OF APOPTOSIS PROTEIN; METHOTREXATE; PREDNISOLONE; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN MDM2; PROTEIN P16; PROTEIN P53; VINCRISTINE;

ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CELL CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE DELETION; GENE LOCUS; GENE OVEREXPRESSION; GENE STRUCTURE; GENETIC DAMAGE; HOMOZYGOSITY; HUMAN; IMMUNOCOMPETENCE; LARGE CELL LYMPHOMA; MALE; MOLECULAR GENETICS; PREDICTION; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGNOSIS; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BRAIN NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE DELETION; GENE EXPRESSION; HUMANS; IMMUNOCOMPETENCE; IMMUNOENZYME TECHNIQUES; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035662765     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012946812930     Document Type: Article

References (33)

1. Primary malignant lymphomas of the central nervous system
2. Primary malignant lymphomas of the central nervous system in man
3. Malignant lymphomas of the nervous system
4. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1985-1989
5. Primary central nervous system lymphoma
6. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
7. Pathogenesis and classification of primary central nervous system lymphoma: An update
8. INK4a (MTS1) in B-cell and T-cell lymphomas
9. Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL
10. INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene
11. Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression
12. Frequent deletion and 5′ CpG island methylation of the p16 gene in primary malignant lymphoma of the brain
13. Mutations of p53 gene and their relation to disease progression in B-cell lymphoma
14. mdm2 oncogene expression in non-Hodgikin's lymphomas
15. Aberrations of the p53 pathway components p53, MDM2 and CDKN2 appear independent in diffuse large B cell lymphoma
16. Chromosomal and gene amplification in diffuse large B-cell lymphoma
17. Bcl-2, Bcl-X, Bax, and Bak expression in short- and long-lived patients with diffuse large B-cell lymphomas
18. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma
19. BCL2 overexpression in diffuse large B-cell lymphoma
20. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma
21. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines
22. Primary central nervous system lymphomas in 72 immunocompetent patients: Pathologic findings and clinical correlations. Groupe Ouest Est d'etude des Leucenies et Autres Maladies du Sang (GOELAMS)
23. Primary central nervous system lymphomas in immunocompetent individuals: Histology, Epstein-Barr virus genome, Ki-67 proliferation index, p53 and bcl-2 gene expression
24. Alterations of the INK4a/ARF locus in human intracranial germ cell tumors
25. Deletion of p16 and p15 genes in brain tumors
26. Molecular analysis for p53 and mdm2 in intracranial germ cell tumors
27. INK4A
28. Tumor surveillance via the ARF-p53 pathway
29. Distinct type of diffuse large B-cell lymphoma identified by gene expression profiling
30. Significance of rearrangement of the BCL6 gene in B-cell lymphoid neoplasms
31. Transcriptional repression by the proto-oncogene BCL-6
32. Bcl-2 and the regulation of programmed cell death
33. Down-regulation of bcl-2 is associated with p16INK4-mediated apoptosis in non-small cell lung cancer cells